Temsirolimus is an mTOR inhibitor used for the treatment of certain types of advanced renal cell carcinoma.

I. Indications

1. Temsirolimus is indicated for the treatment of advanced renal cell carcinoma.

2. Temsirolimus is not recommended for use in combination with sunitinib, as dose-limiting toxicity was observed in clinical trials with this combination regimen.

II. Contraindications

1. Hepatic function contraindications:

(1) Patients with bilirubin >1.5 times the upper limit of normal are contraindicated for temsirolimus.

(2) Such patients have a significantly increased risk of toxicity and death.

2. Allergy contraindications:

Patients with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or any other component of the formulation should use with caution or avoid use.

3. Drug interaction contraindications:

(1) Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, etc.) is contraindicated; if unavoidable, the dose should be reduced to 12.5 mg per week.

(2) Grapefruit juice should also be avoided.

III. Prohibited foods

1. Grapefruit and grapefruit juice:

Grapefruit inhibits the CYP3A4 metabolic enzyme, leading to increased blood concentrations of the active metabolite sirolimus and an increased risk of toxicity.

2. St. John's wort:

This herbal product induces CYP3A4 metabolism, unpredictably reducing temsirolimus blood concentrations; it is prohibited during treatment.

3. High-fat, high-sugar foods:

Because the drug itself tends to cause hyperglycemia and hyperlipidemia, limiting refined sugars and saturated fats is recommended to reduce the need for insulin or lipid-lowering agents.

4. Alcohol:

The temsirolimus injection and diluent both contain dehydrated alcohol; the alcohol content in the prepared solution is up to 35.2%, thus additional alcohol consumption should be avoided.

IV. Special populations

1. Hepatic impairment:

(1) For patients with mild hepatic impairment (bilirubin >1 to 1.5 times the upper limit of normal, or AST > upper limit of normal with normal bilirubin), the dose should be reduced to 15 mg per week.

(2) Patients with moderate or severe hepatic impairment are contraindicated.

2. Renal impairment:

(1) Less than 5% of temsirolimus is excreted in urine; renal impairment is not expected to significantly affect drug exposure, and no dose adjustment is required.

(2) However, no data are available for patients on hemodialysis.

3. Elderly patients:

Patients aged 65 years and older may be more susceptible to adverse reactions such as diarrhea, edema, and pneumonia; close monitoring is recommended during treatment.

4. Pediatric patients:

(1) The efficacy of temsirolimus in pediatric patients with relapsed/refractory solid tumors has not been established.

(2) Pharmacokinetic data show that when dosed based on body surface area, exposure to temsirolimus and sirolimus in children is approximately 6-fold and 2-fold higher, respectively, than in adults; the adverse reactions are similar to those in adults.

5. Pregnant and lactating women:

(1) Animal studies have shown that temsirolimus causes embryo-fetal toxicity and can cause fetal harm.

(2) Women of childbearing potential and men should use effective contraception during treatment and for 3 months after the last dose.

(3) Lactating women should not breastfeed during treatment and for 3 weeks after the last dose.

6. Patients with fertility requirements:

Animal studies have shown that temsirolimus may impair male and female fertility, causing reduced sperm concentration and motility, and increased pre- and post-implantation loss of embryos.